Immune effects of CDK4/6 inhibitors in patients with HR⁺/HER2^- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.

ABSTRACT:

Background

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are innovative small target molecules that, in combination with endocrine therapy, have recently been employed in the treatment of patients with HR⁺/HER2^- metastatic breast cancer (mBC). In this prospective study, we investigate the impact of CDK4/6i on the immune profile of patients with HR⁺/HER2^- mBC.

Methods

Immune cell subsets were analysed using flow cytometry of peripheral blood mononuclear cells (PBMCs) isolated from patients with HR⁺/HER2^- mBC, both before and during treatment. Regulatory T cells (Tregs) were identified using the markers CD4, CD25, CTLA4, CD45RA, and intracellular FOXP3. Monocytic and polymorphonuclear myeloid-derived suppress

SUBMITTER: Scirocchi F 

PROVIDER: S-EPMC9061627 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature